

See “Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis” on page 53-61.

**Supplementary Table 1.** Outcome Measures and Definitions

Efficacy outcome	Hibi et al. (2017) <sup>1</sup>	Kobayashi et al. (2016) <sup>2</sup>	Motoya et al. (2019) <sup>3</sup>	Suzuki et al. (2014) <sup>4</sup>
<b>Induction phase</b>				
Clinical response	-	Clinical response (defined as a decrease in the total Mayo baseline score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute subscore of 0 or 1) at wk 8	Clinical response (defined as a reduction of $\geq 3$ points and $\geq 30\%$ from baseline in the full Mayo score and a $\geq 1$ -point decrease in the rectal bleeding subscore or an absolute rectal bleeding subscore $\leq 1$ ) at wk 10	Clinical response (defined as a full Mayo score decrease of $\geq 3$ points and $\geq 30\%$ from baseline plus a decrease in the rectal bleeding subscore [RBS] $\geq 1$ or an absolute RBS of $\leq 1$ ) at wk 8
Clinical remission	-	Clinical remission (defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point) at wk 8	Clinical remission (defined as a full Mayo score $\leq 2$ and no subscore $> 1$ ) at wk 10	Clinical remission (defined as a full Mayo score $\leq 2$ with no individual subscore $> 1$ ) at wk 8
Mucosal healing	-	Mucosal healing (defined as an endoscopic subscore of 0 or 1) at wk 8	Mucosal healing (defined as an endoscopic subscore $\leq 1$ ) at wk 10	Mucosal healing (defined as an endoscopy subscore $\leq 1$ ) at wk 8
<b>Maintenance phase</b>				
Sustained clinical response	Maintenance of clinical response (defined as a decrease in the Mayo score by $\geq 30\%$ and $\geq 3$ points from induction wk 0, along with a fall in the rectal bleeding subscore of $\geq 1$ or a rectal bleeding subscore of 0 or 1) through wk 54	-	Durable clinical response (defined as a clinical response at both wk 10 and 60)	Clinical response at wk 8 and wk 52
Sustained clinical remission	Clinical remission (defined as a Mayo score of $\leq 2$ points, with no individual subscore $> 1$ ) at both maintenance-wk 30 and maintenance-wk 54	-	Durable remission (defined as having clinical remission at both wk 10 and 60)	Clinical remission at wk 8 and wk 52
Mucosal healing	Mucosal healing (defined as measured using a Mayo endoscopic subscore of 0 or 1) at both maintenance-wk 30 and maintenance-wk 54	Mucosal healing at wk 30	Mucosal healing at wk 60	Mucosal healing at wk 52

- Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo- controlled study-(PURSUIT-J study). *J Gastroenterol* 2017;52:1101-1111.
- Kobayashi T, Suzuki Y, Motoya S, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. *J Gastroenterol* 2016;51:241-251.
- Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. *PLoS One* 2019;14:e0212989.
- Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. *J Gastroenterol* 2014;49:283-294.